Immunocore Holdings (IMCR) Short term Debt (2019)

Immunocore Holdings' (IMCR) quarterly Short term Debt came in at $24.6 million in Q4 2019.

Immunocore Holdings (IMCR) Short term Debt (2019) Analysis & Trends

Immunocore Holdings has disclosed Short term Debt across 1 years of filings, most recently posting $24.6 million for Q4 2019.

  • Short term Debt for Q4 2019 came in at $24.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $24.6 million (changed N/A YoY), and the FY2019 annual result was $24.6 million, changed N/A from the prior year.
  • Short term Debt came in at $24.6 million for Q4 2019 at Immunocore Holdings.
  • In the past five years, Short term Debt ranged from a high of $24.6 million in Q4 2019 to a low of $24.6 million in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
2 Belite Bio 55,234.00 Bn 55,234.00 Bn -
3 Quantum Biopharma 17,823.14 Bn 17,823.14 Bn -
4 Legend Biotech 3,624.50 Bn 3,624.21 Bn 242.10 Mn
5 Akari Therapeutics 1,745.73 Bn 1,745.73 Bn -
6 Evaxion A 1,540.85 Bn 1,540.84 Bn -
7 Psyence Biomedical 229.39 Bn 229.38 Bn -
8 Vertex Pharmaceuticals 112.57 Bn 105.33 Bn 2.59 Bn
9 Abivax 93.46 Bn 93.46 Bn -
10 Immunocore Holdings 1.46 Bn 616.35 Mn 106.24 Mn

Historic Data

Download Data
DateValue
Dec 31, 2019 24.63 Mn